Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Revolution Medicines said it has begun treating patients in its Phase 3 RASolute 309 trial evaluating RASONQUE (daraxonrasib) plus zoldonrasib as a first-line treatment for metastatic RAS G12D pancreatic cancer.
Revolution Medicines starts treating patients in a Phase 3 clinical trial evaluating Zoldonrasib for RAS G12D metastatic pancreatic cancer